Compare Cytokinetics Inc (CYTK) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Roundhill Magnificent Seven ETF — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Roundhill Magnificent Seven ETF trades at $67.48. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | MAGS | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $87.26 | $70.94 |
52-Week Low | $33.23 | $55.39 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.99, down 1.02% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights the ETF's strong performance since launch but notes concentration risk and a recent pullback from 2026 highs. The fund provides equal-weight exposure to mega-cap tech stocks, with assets near $4.7 billion as of May 2026.
The outlook for MAGS hinges on the continued growth and AI monetization of its underlying holdings. Key opportunities include potential free cash flow expansion from hyperscalers, but risks involve high expectations, valuation compression, and the cyclical nature of tech leadership. Market sentiment is mixed, balancing long-term growth prospects against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
